CDP

Card Set Information

Author:
ttelisakberg
ID:
91834
Filename:
CDP
Updated:
2011-06-23 18:34:57
Tags:
CDP
Folders:

Description:
CDP Review
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user ttelisakberg on FreezingBlue Flashcards. What would you like to do?


  1. I: Introduction
    • Clofibrate and Niacin in Coronary Heart Disease
    • JAMA, 1975
    • investigators: Coronary Drug Project Research Group
    • sponsers: National Heart Lung and Blood Institute (NHLBI)
  2. O: Objective
    to test the efficacy and safety of several lipid-lowering drugs in the long-term therapy of CHD in men with previous MI
  3. D: Design (inclusion)
    • 8,341 men; aged 30-64
    • at least 3 months past MI and no worsening of coronary disease
    • Risk Group 1: 1 MI, no complications
    • Risk Group 2: 1+ MI, with complications
  4. D: Design
    • clofibrate: 1.8 g/day
    • niacin: 3.0 g/day
    • placebo
    • 74 months in length
  5. E: Endpoint
    • Primary: total mortality
    • Other major: coronary mortality, sudden death, non-fatal cardio event: recurrent MI, angina, CHF, stroke, pulmonary embolism
  6. Z-values
    • used instead of p-values
    • statistically significant (.01 p-value) with z>2.58 or z<-2.58
    • statistically significant (.005 p-value) with z>2.81 or z<-2.81
    • negative z-values denotes event rate lower in drug arm v. placebo
    • further z-value from 0; more statistically significant
  7. R: Results (niacin endpoints)
    • Death: clo (25.5%), nia (24.4%), placebo(25.4%) statistically insignificant
  8. R: Results (lipids)
    • clofibrate: TC (-6.5%), TGs (-22.3%)
    • niacin: TC (-9.9%), TGs (-26.1%)
  9. R: Results (safety/side effects)
    Dropout Rates: clofibrate (77.1%), niacin (66.2%), palcebo (77.8%)
  10. Baselines

What would you like to do?

Home > Flashcards > Print Preview